Immunovant Inc
IMVT
Insidertransaktionen und Aktienkurs 2024-2026
Alle Insidertrades bei Immunovant Inc
| Datum |
Typ |
Insider |
Position |
Ø-Preis |
Volumen |
|
24.7.2026
|
Verkauf |
Pande, Atul |
Aufsichtsrat |
39,8 $ |
59.700 $ |
|
23.7.2026
|
Verkauf |
Girao, Tiago |
Chief Financial Officer |
38,7 $ |
263.015 $ |
|
23.7.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
38,7 $ |
110.537 $ |
|
8.7.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
39,8 $ |
137.924 $ |
|
8.7.2026
|
Verkauf |
Van Tuyl Christopher |
Chief Legal Officer |
39,8 $ |
47.702 $ |
|
8.7.2026
|
Verkauf |
Gloria, Melanie |
Chief Operating Officer |
39,8 $ |
80.532 $ |
|
2.7.2026
|
Verkauf |
Venker, Eric |
Chief Executive Officer |
38,5 $ |
118.980 $ |
|
26.6.2026
|
Verkauf |
Pande, Atul |
Aufsichtsrat |
38,0 $ |
57.015 $ |
|
26.6.2026
|
Verkauf |
Girao, Tiago |
Chief Financial Officer |
38,5 $ |
384.600 $ |
|
26.6.2026
|
Verkauf |
Van Tuyl Christopher |
Chief Legal Officer |
38,6 $ |
682.887 $ |
|
26.6.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
38,6 $ |
1.532.310 $ |
|
26.6.2026
|
Verkauf |
Gloria, Melanie |
Chief Operating Officer |
38,6 $ |
678.605 $ |
|
18.6.2026
|
Verkauf |
Van Tuyl Christopher |
Chief Legal Officer |
35,4 $ |
93.217 $ |
|
15.6.2026
|
Verkauf |
Pande, Atul |
Aufsichtsrat |
34,0 $ |
51.030 $ |
|
28.5.2026
|
Verkauf |
Fromkin, Drew J. |
Aufsichtsrat |
33,1 $ |
7.438.111 $ |
|
20.5.2026
|
Verkauf |
Pande, Atul |
Aufsichtsrat |
32,0 $ |
192.000 $ |
|
20.5.2026
|
Verkauf |
Gloria, Melanie |
Chief Operating Officer |
31,8 $ |
101.072 $ |
|
1.5.2026
|
Verkauf |
Susman, Robert Graham |
Aufsichtsrat |
27,2 $ |
67.979 $ |
|
23.4.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
29,6 $ |
81.573 $ |
|
23.4.2026
|
Verkauf |
Girao, Tiago |
Chief Financial Officer |
29,6 $ |
763.011 $ |
|
8.4.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
24,8 $ |
251.578 $ |
|
8.4.2026
|
Verkauf |
Van Tuyl Christopher |
Chief Legal Officer |
24,8 $ |
128.247 $ |
|
8.4.2026
|
Verkauf |
Gloria, Melanie |
Chief Operating Officer |
24,8 $ |
216.567 $ |
|
2.4.2026
|
Verkauf |
Venker, Eric |
Chief Executive Officer |
24,3 $ |
342.854 $ |
|
18.3.2026
|
Verkauf |
Van Tuyl Christopher |
Chief Legal Officer |
25,0 $ |
71.839 $ |
|
25.2.2026
|
Verkauf |
Gloria, Melanie |
Chief Operating Officer |
28,0 $ |
90.183 $ |
|
21.1.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
26,0 $ |
51.461 $ |
|
7.1.2026
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
26,7 $ |
31.914 $ |
|
18.12.2025
|
Verkauf |
Van Tuyl Christopher |
Chief Legal Officer |
27,1 $ |
290.943 $ |
|
12.12.2025
|
Kauf |
Roivant Sciences Ltd. |
Aufsichtsrat |
21,0 $ |
349.999.986 $ |
|
1.12.2025
|
Verkauf |
Hughes, Douglas J. |
Aufsichtsrat |
23,6 $ |
348.666 $ |
|
1.12.2025
|
Verkauf |
Fromkin, Drew J. |
Aufsichtsrat |
23,6 $ |
517.189 $ |
|
20.11.2025
|
Verkauf |
Gloria, Melanie |
Chief Operating Officer |
23,8 $ |
298.238 $ |
|
22.10.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
19,0 $ |
47.956 $ |
|
22.10.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
19,0 $ |
49.383 $ |
|
8.10.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
16,3 $ |
25.836 $ |
|
8.10.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
16,3 $ |
20.734 $ |
|
23.7.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
18,2 $ |
43.288 $ |
|
23.7.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
18,2 $ |
50.911 $ |
|
9.7.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
17,2 $ |
26.188 $ |
|
9.7.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
17,2 $ |
19.998 $ |
|
23.4.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
14,8 $ |
34.742 $ |
|
23.4.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
14,8 $ |
28.471 $ |
|
16.4.2025
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
14,9 $ |
123.900 $ |
|
16.4.2025
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
14,9 $ |
44.566 $ |
|
9.4.2025
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
13,0 $ |
364.941 $ |
|
9.4.2025
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
13,0 $ |
143.709 $ |
|
9.4.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
13,0 $ |
80.135 $ |
|
9.4.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
13,0 $ |
65.002 $ |
|
7.3.2025
|
Verkauf |
Fromkin, Drew J. |
Aufsichtsrat |
19,7 $ |
156.769 $ |
|
19.2.2025
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
20,9 $ |
322.058 $ |
|
19.2.2025
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
20,9 $ |
58.700 $ |
|
19.2.2025
|
Verkauf |
Macias, William L. |
Chief Medical Officer |
20,9 $ |
42.867 $ |
|
22.1.2025
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
23,6 $ |
62.679 $ |
|
22.1.2025
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
23,6 $ |
51.780 $ |
|
15.1.2025
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
24,0 $ |
208.900 $ |
|
15.1.2025
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
24,0 $ |
54.757 $ |
|
15.1.2025
|
Verkauf |
Macias, William L. |
Chief Medical Officer |
24,0 $ |
56.782 $ |
|
13.1.2025
|
Kauf |
Roivant Sciences Ltd. |
Aufsichtsrat |
20,0 $ |
336.900.200 $ |
|
8.1.2025
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
24,1 $ |
123.031 $ |
|
8.1.2025
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
24,1 $ |
98.931 $ |
|
2.12.2024
|
Verkauf |
Hughes, Douglas J. |
Aufsichtsrat |
28,5 $ |
154.830 $ |
|
2.12.2024
|
Verkauf |
Pande, Atul |
Aufsichtsrat |
28,5 $ |
221.185 $ |
|
20.11.2024
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
25,4 $ |
424.811 $ |
|
20.11.2024
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
25,4 $ |
106.228 $ |
|
20.11.2024
|
Verkauf |
Macias, William L. |
Chief Medical Officer |
25,4 $ |
85.334 $ |
|
20.11.2024
|
Verkauf |
Levine, Mark S. |
Chief Legal Officer |
25,4 $ |
92.893 $ |
|
23.10.2024
|
Verkauf |
Stout, Jay S. |
Chief Technology Officer |
29,5 $ |
80.912 $ |
|
23.10.2024
|
Verkauf |
Geffner, Michael |
Chief Medical Officer |
29,5 $ |
94.171 $ |
|
23.10.2024
|
Verkauf |
Levine, Mark S. |
Chief Legal Officer |
29,5 $ |
128.780 $ |
|
16.10.2024
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
28,8 $ |
94.172 $ |
|
16.10.2024
|
Verkauf |
Levine, Mark S. |
Chief Legal Officer |
28,8 $ |
82.339 $ |
|
16.10.2024
|
Verkauf |
Macias, William L. |
Chief Medical Officer |
28,8 $ |
91.782 $ |
|
16.10.2024
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
28,8 $ |
261.845 $ |
|
9.10.2024
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
29,6 $ |
131.838 $ |
|
9.10.2024
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
29,6 $ |
152.589 $ |
|
21.8.2024
|
Verkauf |
Salzmann, Peter |
Chief Executive Officer |
32,1 $ |
480.052 $ |
|
21.8.2024
|
Verkauf |
Butchko, Julia G. |
Chief Development Officer |
32,1 $ |
96.437 $ |
|
21.8.2024
|
Verkauf |
Barnett, Eva Renee |
Chief Financial Officer |
32,1 $ |
120.045 $ |
|
21.8.2024
|
Verkauf |
Macias, William L. |
Chief Medical Officer |
32,1 $ |
96.437 $ |
|
21.8.2024
|
Verkauf |
Levine, Mark S. |
Chief Legal Officer |
32,1 $ |
104.976 $ |
Alle Angaben ohne Gewähr! Keine Empfehlung/Beratung! © U.S. Securities and Exchange Commission (SEC)
Kostenlose Updates per Mail
Bestätige noch deine Email-Adresse